Get started
Author

Nicholas Kigen

Dental fluorosis and oral health in the African Esophageal Cancer Corridor: Findings from the Kenya ESCCAPE case–control study and a pan‐African perspective
2018 · Diana Menya, Stephen K. Maina, et al. · International Journal of Cancer · 93
PDF
Hot beverages and oesophageal cancer risk in western Kenya: Findings from the ESCCAPE case–control study
2018 · Daniel RS Middleton, Diana Menya, et al. · International Journal of Cancer · 70
PDF
Traditional and commercial alcohols and esophageal cancer risk in Kenya
2018 · Diana Menya, Nicholas Kigen, et al. · International Journal of Cancer · 62
PDF
Cancer epidemiology fieldwork in a resource-limited setting: Experience from the western Kenya ESCCAPE esophageal cancer case-control pilot study
2018 · Diana Menya, Margaret Oduor, et al. · Cancer Epidemiology · 9
PDF
Improvement of diagnosis in children with Burkitt lymphoma in Kenya: feasibility study for the implementation of fluorescence in situ hybridisation testing for MYC and the MYC/IGH translocation
2023 · Gail H Vance, Teresa Lotodo, et al. · ecancermedicalscience · 3
PDF
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV · 2
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet · 1
Prospective Cohort Study Testing Interventions to Reduce Diagnosis Delay and Treatment Abandonment of Children With Burkitt Lymphoma in Kenya
2026 · Sandra Langat, Festus Njuguna, et al. · JCO Global Oncology · 1
PDF
Introducing Diagnostic Testing for Chronic Myeloid Leukemia in a Public Hospital Setting in Western Kenya
2025 · Millicent Orido, Teresa Cherop Lotodo, et al. · Archives of Pathology & Laboratory Medicine · 1
CD34-Negative B-Lymphoblastic Leukemia/Lymphoma Presenting as Cutenous Lesions at Infancy: A Case Report
2022 · Teresa Lotodo, Festus Njuguna, et al. · Journal of Biosciences and Medicines · 1
PDF
Diagnostic and health system constraints in pediatric hematologic malignancies in East Africa and implications for WHO classification reconsidering in limited resource settings
2026 · Terry Vik, Steven Kussick, et al. · Discover Oncology
Using flow cytometry for paediatric leukaemia diagnosis in Kenya: a protocol for mixed methods study
2026 · Tyler Severance, Teresa Lotodo, et al. · BMJ Open
PDF
Works count: 13
Citation count: 245
H-index: 4
I10-index: 3
Year
Topic
Type